Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Trial Profile

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Aldoxorubicin (Primary) ; ALT 803 (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; CD16 and interleukin 2 expressing natural killer cells-NantKwest (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; GI 4000 (Primary) ; Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors NantKwest
  • Most Recent Events

    • 08 Nov 2018 According to CytRx Corporation Media Release, data from the Phase 1b portion will be Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
    • 08 Nov 2018 Results published in the CytRx Corporation Media Release
    • 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top